Simris Alg AB, a European biologics company focused on extracting high value biological active compounds from microalgae and cyanobacteria, entered into collaboration agreement with Lonza Ltd. to commercialize Simris’ antibody drug conjugates (ADC) payload platform. With more than 210 novel ADC clinical trials started in 2022, the market for ADC medicines continues to develop in line with their recognition as effective, stable and reliable cancer therapeutics. Novel payloads with novel mod...